FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 319:599-604 September 8, 1988 Number 10 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We randomly assigned 46 patients (mean age, 11.7 years; range, 4.5 to 32.8) with newly diagnosed insulin-dependent diabetes mellitus within two weeks of beginning insulin to receive either corticosteroids for 10 weeks plus daily azathioprine for one year or no immunosuppressive therapy. Half the 20 immunosuppressed patients completing the one-year trial had satisfactory metabolic outcomes (hemoglobin A1c less than 6.8 percent; stimulated peak C peptide greater than 0.5 nmol per liter; insulin dose less than 0.4 U per kilogram of body weight per day) as compared with only 15 percent of the controls. Three of 20 immunosuppressed patients, but no controls, were insulin independent at one year. Two of these continue to receive azathioprine without insulin after more than 27 months of follow-up. The response to immunosuppression correlated with older age, better initial metabolic status, and lymphopenia (less than 1800 lymphocytes per cubic millimeter) resulting from immunosuppression. The side effects of azathioprine included vomiting in one patient and mild hair loss in several others. Prednisone use resulted in a transient cushingoid appearance, weight gain, and hyperglycemia. The growth rate remained normal in all patients. We conclude that early immunosuppression with short-term use of corticosteroids plus daily azathioprine can improve metabolic control in some patients with insulin-dependent diabetes mellitus, but results from this unblinded study are preliminary and require further confirmation and long-term follow-up.

Source Information

Department of Pediatrics, University of Florida, Gainesville.

This article has been cited by other articles:

• Voltarelli, J. C., Couri, C. E. B., Stracieri, A. B. P. L., Oliveira, M. C., Moraes, D. A., Pieroni, F., Coutinho, M., Malmegrim, K. C. R., Foss-Freitas, M. C., Simoes, B. P., Foss, M. C., Squiers, E., Burt, R. K. (2007). Ethics of Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus--Reply. JAMA 298: 285-286 [Full Text]  
• Voltarelli, J. C., Couri, C. E. B., Stracieri, A. B. P. L., Oliveira, M. C., Moraes, D. A., Pieroni, F., Coutinho, M., Malmegrim, K. C. R., Foss-Freitas, M. C., Simoes, B. P., Foss, M. C., Squiers, E., Burt, R. K. (2007). Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus. JAMA 297: 1568-1576 [Abstract] [Full Text]  
• Haller, M. J., Schatz, D. A., Schwartz, I. D., Keymeulen, B., Pipeleers, D., Chatenoud, L. (2005). CD3-antibody therapy in new-onset type 1 diabetes mellitus.. NEJM 353: 2086-2087 [Full Text]  
• Narendran, P., Estella, E., Fourlanos, S. (2005). Immunology of type 1 diabetes. QJM 98: 547-556 [Full Text]  
• Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D. M., Bluestone, J. A. (2005). A Single Course of Anti-CD3 Monoclonal Antibody hOKT3{gamma}1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes. Diabetes 54: 1763-1769 [Abstract] [Full Text]  
• Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., Steffes, M. W. (2004). C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001. Diabetes 53: 250-264 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2003). Diabetes Issues in Women and Children: Polycystic ovary syndrome. Diabetes Care 26: 2457-2463 [Full Text]  
• Greenbaum, C. J., Harrison, L. C. (2003). Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes. Diabetes 52: 1059-1065 [Full Text]  
• Brod, S. A. (2002). Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity. Exp. Biol. Med. 227: 981-988 [Abstract] [Full Text]  
• Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., Bluestone, J. A. (2002). Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus. NEJM 346: 1692-1698 [Abstract] [Full Text]  
• Atkinson, M. A., Maclaren, N. K. (1994). The Pathogenesis of Insulin-Dependent Diabetes Mellitus. NEJM 331: 1428-1436 [Full Text]  
• (1988). MORE EVIDENCE FOR SHORT-TERM BENEFIT OF IMMUNOSUPPRESSIVE THERAPY IN DIABETES. JWatch General 1988: 6-6 [Full Text]